98%
921
2 minutes
20
Purpose: This study presents NeuroDL, a novel deep learning-based diagnostic framework designed for the automated detection of brain tumors and Alzheimer's disease (AD) using magnetic resonance imaging (MRI). The objective is to enhance diagnostic precision and efficiency in neurology through advanced computer-aided decision support.
Methods: NeuroDL utilizes convolutional neural networks (CNNs) trained on two publicly available, annotated MRI datasets. The proposed pipeline integrates optimized preprocessing, including normalization, skull stripping, and data augmentation, followed by CNN-based feature extraction and classification. Transfer learning and fine-tuning were employed to improve generalization on limited medical data.
Results: Experimental evaluations show that NeuroDL achieves 96.8% classification accuracy for brain tumor detection and 92.4% accuracy for Alzheimer's disease diagnosis. The method also achieves an average F1-score of 0.965, precision of 0.969, and recall of 0.962 for brain tumors, and an F1-score of 0.918, precision of 0.921, and recall of 0.916 for AD. These results outperform state-of-the-art benchmarks on the same datasets.
Conclusion: Potential for real-time clinical deployment. It addresses key limitations of existing CAD systems by providing a unified, dual-disease diagnosis model with statistically validated performance gains. NeuroDL paves the way for reliable, scalable, and automated neurological disease diagnosis using deep learning.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373713 | PMC |
http://dx.doi.org/10.1002/brb3.70788 | DOI Listing |
J Neurooncol
September 2025
Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Purpose: Glioblastoma (GBM) remains one of the most aggressive primary brain tumors with poor survival outcomes and a lack of approved therapies. A promising novel approach for GBM is the application of photodynamic therapy (PDT), a localized, light-activated treatment using tumor-selective photosensitizers. This narrative review describes the mechanisms, delivery systems, photosensitizers, and available evidence regarding the potential of PDT as a novel therapeutic approach for GBM.
View Article and Find Full Text PDFJ Neurooncol
September 2025
Department of Radiation Oncology, Massachusetts General Hospital, Boston, USA.
Purpose: Cranial irradiation is associated with health-related quality of life (HRQoL) deficits in childhood cancer survivors. We investigated the relationship between radiation dose to brain substructures and HRQoL in children with brain tumors treated with proton beam therapy (PBT).
Methods: Data were obtained from children in the Pediatric Proton/Photon Consortium Registry who received PBT for primary brain tumors between 2015 and 2021.
J Neurooncol
September 2025
Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Purpose: NOTCH3 is increasingly implicated for its oncogenic role in many malignancies, including meningiomas. While prior work has linked NOTCH3 expression to higher-grade meningiomas and treatment resistance, the metabolic phenotype of NOTCH3 activation remains unexplored in meningioma.
Methods: We performed single-cell RNA sequencing on NOTCH3 + human meningioma cell lines.
Neurosurg Rev
September 2025
Service de Neurochirurgie, GHU-Paris Psychiatrie et Neurosciences, Site Sainte Anne, Paris, F-75014, France.
Awake craniotomy is the gold standard to achieve maximal safe resection of brain lesions located within eloquent areas. There are no established guidelines to assess patient's eligibility for awake craniotomy by weight class. This study assesses feasibility, safety, and efficacy of awake surgery by weight classes through an observational, retrospective, single-institution cohort analysis (2010-2024) of 526 awake craniotomies.
View Article and Find Full Text PDFNeurosurg Rev
September 2025
Department of Neurosurgery, University Hospital of Ioannina, Ioannina, Greece.
Background: The aim of this review is to present the role of intraoperative flow cytometry (IFC) in the intracranial tumor surgery. This scoping review aims to summarize current evidence on the intraoperative use of IFC in patients with intracranial tumors.
Methods: A comprehensive literature search was conducted in the Medline, Cochrane and Scopus databases up to January 21, 2025.